Boehringer Ingelheim and Zhangjiang Biotech & Pharmaceutical Base Developmentof Pudong, Shanghai have allied to build a cGMP biopharmaceuticals facility. The site will provide development and clinical services to Chinese and multi-national customers. It will utilize mammalian cell culture technology.
The facility will include technical process development and cGMP manufacturing by early 2016. Boehringer Ingelheim plans to invest approximately $46 million. The project will create up to 65 job opportunities with high qualification standards.
“Shanghai is our ideal partner with its advantages in investment environment, service system and talent resources,” said Christian Boehringer, chairman of the shareholders committee.
“With a number of innovative medicines being developed by a cluster of middle to small-sized innovative companies in Zhangjiang, plus the government support, we plan to initiate the CMO manufacturing framework at this plant on a trial basis,” said Lanzhong Wang, general manager of Zhangjiang. “This will provide an effective platform for middle and small-sized companies to industrialize their innovations. Thus, it will greatly prompt the development of China's biopharmaceuticals manufacturing industry."